ALS Awareness Month: Day 27

Clearly the ALS community still has a long way to go to finding a cure, or even effective treatment options. And that’s also why fundraising is such an important part of what we do here at the RASCALS Foundation.

Categories: 501(c)(3) Non-Profit, Research News, Technology, Treatments  |  Tags: 501(c)(3) ALS charity, additional ALS genes, ALS, ALS Awareness Month, ALS community, ALS medical care, ALS research, ALS survival rates, ALS treatments, amyotrophic lateral sclerosis, apoptosis, biological marker for ALS, Bob Stehlin, familial ALS, genetic risk factors ALS, Lou Gehrig’s disease, minocycline to treat ALS, mortality ALS, National Institute of Neurological Disorders and Stroke, neuroprotective strategies, neurotrophic factors, PALS, Potential therapies for ALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mutations, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis  |  No comments